MedTrace Logo

Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

NCT04925557 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-05-13

Study results available
· View outcomes & findings →

Summary

To assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the lesional and non-lesional NAWM and NAGM and in the peri-plaque area of chronic lesions in the brain.

Conditions

  • Secondary-progressive Multiple Sclerosis

Interventions

DRUG

Mayzent

PET imaging to evaluate the effects of Mayzent on the microglia of the brain.

DRUG

Ocrevus

PET imaging to evaluate the effects of Ocrevus on the microglia of the brain.

Sponsors & Collaborators

  • State University of New York at Buffalo

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-13
Primary Completion
2023-06-01
Completion
2023-08-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04925557 on ClinicalTrials.gov